Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications

This publication has 22 references indexed in Scilit:

• Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure
  Health Affairs, 2016
• Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt
  Value in Health Regional Issues, 2013
• Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
  ClinicoEconomics and Outcomes Research, 2012
• Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis
  PharmacoEconomics, 2011
• Spanish recommendations on economic evaluation of health technologies
  The European Journal of Health Economics, 2010
• Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II
  Value in Health, 2010
• Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I
  Value in Health, 2010
• Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report—Part V
  Value in Health, 2010
• Future Drug Prices and Cost-Effectiveness Analyses
  PharmacoEconomics, 2008
• Impact of Generic Drug Entry on Cost-Effectiveness Analysis
  Medical Decision Making, 2005